Orphan drug designation is reserved for medicines treating rare, life-threatening or chronically debilitating diseasesIgA nephropathy (IgAN), while rare, is the most common form of glomerulonephritis, affecting mostly young adults with no approved trea…
Huntington’s disease is a rare, inherited neurodegenerative disease that leads to progressive disability and deathThere are no approved disease modifying therapies that delay disease onset or slow progression of the diseaseBranaplam (LMI070) is an oral…
If approved, inclisiran will be the first and only small interfering RNA (siRNA) in Europe for patients with hypercholesterolemia or mixed dyslipidemia1Cardiovascular disease (CVD) claims 3.9 million lives annually in Europe2, and 80% of high-risk…
The European Medicines Agency has granted iptacopan a priority medicines (PRIME) designation in C3 glomerulopathy (C3G). PRIME is granted for medicines that may offer major therapeutic advance or benefit patients without treatment options.C3 glomerulop…
2.2 billion people are blind or visually impaired worldwide. Half of them lack access to eye care. Together, we are working to change that. This World Sight Day, Novartis is proud to partner with the International Agency for the Prevention of Blindness…
In a post-hoc analysis of HAWK and HARRIER, fewer Beovu (brolucizumab) patients had early persistent fluid (12.5% vs. 20.4% of aflibercept patients), defined as the presence of intra-retinal fluid and/or sub-retinal fluid through week 12 of treatment1P…
Nearly two-thirds of patients (65.6%) in STR1VE-EU have already achieved developmental motor milestones not observed in the natural history of SMA Type 1 at a mean duration of follow-up of 10.6 months, including patients with a more severe phenotype co…
COVID-19’s existence anywhere poses a threat to communities everywhere. The health, social, and economic impacts can only be addressed through the collective actions of stakeholders across private, public, and philanthropic sectors in partnership with …
For the past six decades, Novartis has been working to advance heart health around the world, from transforming the standard of care for cardiovascular conditions to strengthening healthcare systems in lower income communities.Cardiovascular disease (C…
Although Chagas disease was discovered more than a century ago, it remains a major public health challenge. Chagas disease affects approximately six million people, mainly in Latin America. Yet, less than 1% of affected individuals receive proper anti-…